Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 2;385(10):951-953.
doi: 10.1056/NEJMc2108829. Epub 2021 Jul 14.

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination

Dan H Barouch  1 , Kathryn E Stephenson  1 , Jerald Sadoff  2 , Jingyou Yu  3 , Aiquan Chang  3 , Makda Gebre  3 , Katherine McMahan  3 , Jinyan Liu  3 , Abishek Chandrashekar  3 , Shivani Patel  3 , Mathieu Le Gars  2 , Anne M de Groot  2 , Dirk Heerwegh  4 , Frank Struyf  4 , Macaya Douoguih  2 , Johan van Hoof  2 , Hanneke Schuitemaker  2
Affiliations

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination

Dan H Barouch et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Humoral and Cellular Immune Responses after Ad26.COV2.S Vaccination.
Panel A shows binding antibody titers against the receptor-binding domain (RBD) of the parental WA1/2020 strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by enzyme-linked immunosorbent assays (ELISA), pseudovirus neutralizing antibody assays, and intracellular cytokine staining assays showing spike-specific CD8+ and CD4+ T-cell responses on days 29, 57, 71 or 85, and 239. Participants received the Ad26.COV2.S vaccine in one or two doses of either 1011 viral particles (vp) or 5×1010 vp. Red arrows indicate one vaccine recipient who had breakthrough SARS-CoV-2 infection (who had received a single dose of 1011 vp) and two recipients who had also received a messenger RNA vaccine (who had received two doses of 5×1010 vp) between days 71 and 239. The horizontal dashed line indicates the lower limit of quantitation. Panel B shows pseudovirus neutralizing antibody titers against the parental WA1/2020 strain as well as the SARS-CoV-2 variants D614G, B.1.1.7 (alpha), B.1.617.1 (kappa), B.1.617.2 (delta), P.1 (gamma), B.1.429 (epsilon), and B.1.351 (beta) on days 29 and 239. Panel C shows pseudovirus neutralizing antibody titers on day 239 following Ad26.COV2.S vaccination after the exclusion of the three above-mentioned participants (at left) and after restriction of the analysis to participants who received a single dose of the Ad26.COV2.S vaccine (at right). In Panels B and C, the horizontal red bar indicates the median response. For the two-dose vaccine, immunizations were administered on days 1 and 57.
See this image and copyright information in PMC

Update of

References

    1. Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 2021;384:2187-2201. - PMC - PubMed
    1. Stephenson KE, Le Gars M, Sadoff J, et al. Immunogenicity of the Ad26.COV2.S vaccine for COVID-19. JAMA 2021;325:1535-1544. - PMC - PubMed
    1. Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1–2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med 2021;384:1824-1835. - PMC - PubMed
    1. Salisch NC, Stephenson KE, Williams K, et al. A double-blind, randomized, placebo-controlled phase 1 study of Ad26.ZIKV.001, an Ad26-vectored anti-Zika virus vaccine. Ann Intern Med 2021;174:585-594. - PubMed
    1. Doria-Rose N, Suthar MS, Makowski M, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. N Engl J Med 2021;384:2259-2261. - PMC - PubMed

Publication types